Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Routes of Persuasion

Routes of Persuasion

Persuasion is the process of changing our attitude toward something based on some kind of communication. Much of the persuasion we experience comes from outside forces. How do people convince others to change their attitudes, beliefs, and behaviors? What communications do you receive that attempt to persuade you to change your attitudes, beliefs, and behaviors?

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Further insights into the application of the TFR prognostic score (TPS) in CML patients attempting TFR.

British journal of haematology·2026

Same author

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026

Same author

A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia.

International journal of molecular sciences·2026

Same author

Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.

British journal of haematology·2026

Same author

Pregnancy after hematopoietic stem cell transplant: an international multicenter study.

Blood advances·2026

Same author

Corrigendum to "Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group" [Modern Pathology. 2024;37(2):100406].

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025

Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025

Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025

Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 1, 2026

Uncovering Beat Deafness: Detecting Rhythm Disorders with Synchronized Finger Tapping and Perceptual Timing Tasks

Uncovering Beat Deafness: Detecting Rhythm Disorders with Synchronized Finger Tapping and Perceptual Timing Tasks

Published on: March 16, 2015

The argument for using imatinib in CML.

Simone Claudiani^1,2, Jane F Apperley^1,2

¹Department of Clinical Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom; and.

Hematology. American Society of Hematology. Education Program

|December 4, 2018

Summary

This summary is machine-generated.

The management of chronic myeloid leukemia has evolved significantly with tyrosine kinase inhibitors (TKIs). This review explores TKI selection and treatment discontinuation strategies for improved patient outcomes.

More Related Videos

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Published on: June 16, 2011

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

Related Experiment Videos

Last Updated: Feb 1, 2026

Uncovering Beat Deafness: Detecting Rhythm Disorders with Synchronized Finger Tapping and Perceptual Timing Tasks

Uncovering Beat Deafness: Detecting Rhythm Disorders with Synchronized Finger Tapping and Perceptual Timing Tasks

Published on: March 16, 2015

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Published on: June 16, 2011

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

Area of Science:

Hematology
Oncology
Pharmacology

Background:

The 20th anniversary of imatinib highlights the success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).
Patient management has shifted from delaying disease progression to optimizing TKI choice, managing side effects, and considering treatment cessation.
The availability of multiple frontline TKIs introduces complexity and controversy in treatment selection.

Purpose of the Study:

To explore factors influencing the choice of frontline tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).
To provide a pragmatic and clinically applicable solution for TKI selection and treatment discontinuation strategies.

Main Methods:

Review of current clinical practices and emerging evidence in CML management.
Analysis of factors influencing TKI selection, including efficacy, safety, and patient-specific considerations.
Discussion of strategies for treatment-free remission and therapy discontinuation.

Main Results:

The choice of frontline TKI in CML remains a complex decision with ongoing debate.
Management now encompasses quality of life, comorbidities, adverse effects, and the potential for treatment discontinuation.
Treatment-free remission is a growing consideration, influencing therapeutic strategies.

Conclusions:

Optimizing TKI selection and exploring treatment discontinuation are crucial for improving CML patient outcomes.
A pragmatic approach is needed to navigate the complexities of modern CML therapy.
Further research and clinical guidance are essential for personalized CML management.